Mission Statement
Clinical needs in cancer are still unmet. Current therapies lack efficacy and the most effective medications are also quite toxic. The mission of DanDrit Biotech A/S is to provide safe and efficacious vaccines to cancer patients, worldwide.
To fulfill this mission we will:
- Continue to develop new vaccines.
- Test our vaccines in clinical trials.
- Obtain marketing approval in the shortest possible time.
- Establish strong collaboration with academic institutions, cancer clinics/hospitals and the industry.
- Be considered an attractive company to work with, and thus attract the most skilful researchers and technical personnel.
- Maximize long-term shareholder value.
Strategy
Our objective is to establish our position as a leader in the development and marketing of biological products for the treatment and control of cancer.
Key aspects of our corporate strategy include the following:
- Obtain regulatory approval of MelCancerVac® for the treatment of patients with solid tumors.
- Directly market or co-promote MelCancerVac® in Europe and establish strategic collaborations to market MelCancerVac® in the rest of World.
- Expand our product pipeline and technologies through acquisitions and in-licensing.
- Leverage our in-house manufacturing capabilities to support the commercialization of MelCancerVac® and our product candidates.